FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311760376> ?p ?o ?g. }

• W4311760376 abstract "Abstract Transcatheter treatment of degenerated aortic bioprostheses is nowadays a well-established option (Valve-in-vale, ViV); however, some patients may pose some specific challenges. Perceval® is a sutureless, stent-mounted, aortic valve bioprosthesis that can be placed with a less invasive surgical technique. Its nitinol self-expandable stent frame is a bulky structure that anchors to the aortic annulus without the need of continuous suture, thus reducing aortic cross-clamp and cardiopulmonary bypass time. Performing transcatheter aortic valve replacement (TAVR) in Perceval® may be associated with increased risk of coronary obstruction, impaired coronary access and increased post-procedural gradients. Here we present the cases of two patients with Perceval® degeneration that have been treated with two different tailored approaches following a dedicated Heart Team evaluation. R.M. is a 74-year-old, very low-weight, woman with a history of diabetes, severe COPD, 3b stage CKD, rheumatoid arthritis and previous carotid surgery. She underwent surgical aortic valve replacement (SAVR) with Perceval® “S” bioprosthesis for severe aortic stenosis in 2016. After five years she was diagnosed with severe symptomatic degeneration of the aortic prosthesis (mean gradient 45 mmHg, NYHA class III). The patient was therefore discussed by the Heart Team and scheduled for percutaneous treatment. A ViV with a self-expandable Medtronic 23 mm Evolut™ R bioprosthesis was successfully performed. Hospital stay was uneventful and the patient was discharged on 6th post-operative day in good clinical conditions and good functional class. S.R. is a 70-year-old active smoker woman with a history of previous hemicolectomy for cancer that underwent SAVR in ministernotomy for severe aortic stenosis with Perceval® “L” in 2015. In 2016 she underwent PCI + DES implantation on OM of LCX for an acute coronary syndrome. In 2022 she was diagnosed with severe symptomatic degeneration of the bioprosthesis (mean gradient 40 mmHg, NYHA class II). The patient was referred to Heart Team discussion and scheduled for surgical reintervention. She underwent successful surgery with implantation of a Medtronic Avalus™ 23 mm bioprosthesis, followed by regular rehabilitation. In the first case the severe comorbidities and frailty made the surgical risk almost prohibitive for reintervention (STS-M 9,23%, STS-MM 23,7%, Euroscore II 6,18%). Moreover, there was very little concern about the risk of impaired coronary access afterwards. The second patient, instead, had an acceptable risk for surgery (STS-M 2,2%, STS-MM 10,6%, Euroscore II 4.45%); there was also a significant concern about the risk of impaired coronary access in case of ViV, since she already had a history of percutaneous coronary revascularization. Furthermore, from a lifetime management point of view it is possible to hypothesize easier future reintervention with a TAVR in SAVR instead of a complex TAVR in TAVR in SAVR. Thus, although ViV was technically feasible in both cases with predictable good short-term outcomes, we decided for opposite treatments by looking at individualized long-term needs. In Conclusion the choice between surgical and transcatheter intervention must be based not only on careful evaluation of clinical, anatomical and procedural characteristics but also on future perspectives, especially in patients with longer life expectancy." @default.
• W4311760376 created "2022-12-28" @default.
• W4311760376 creator A5039284492 @default.
• W4311760376 creator A5045389897 @default.
• W4311760376 creator A5050221975 @default.
• W4311760376 creator A5052731078 @default.
• W4311760376 creator A5077826753 @default.
• W4311760376 creator A5086426607 @default.
• W4311760376 creator A5088253639 @default.
• W4311760376 date "2022-12-14" @default.
• W4311760376 modified "2023-10-15" @default.
• W4311760376 title "672 TRANSCATHETER VS SURGICAL TREATMENT FOR PERCEVAL DEGENERATION: TAILORED STRATEGY FROM THE HEART TEAM" @default.
• W4311760376 doi "https://doi.org/10.1093/eurheartjsupp/suac121.285" @default.
• W4311760376 hasPublicationYear "2022" @default.
• W4311760376 type Work @default.
• W4311760376 citedByCount "0" @default.
• W4311760376 crossrefType "journal-article" @default.
• W4311760376 hasAuthorship W4311760376A5039284492 @default.
• W4311760376 hasAuthorship W4311760376A5045389897 @default.
• W4311760376 hasAuthorship W4311760376A5050221975 @default.
• W4311760376 hasAuthorship W4311760376A5052731078 @default.
• W4311760376 hasAuthorship W4311760376A5077826753 @default.
• W4311760376 hasAuthorship W4311760376A5086426607 @default.
• W4311760376 hasAuthorship W4311760376A5088253639 @default.
• W4311760376 hasBestOaLocation W43117603761 @default.
• W4311760376 hasConcept C126322002 @default.
• W4311760376 hasConcept C141071460 @default.
• W4311760376 hasConcept C164705383 @default.
• W4311760376 hasConcept C176752191 @default.
• W4311760376 hasConcept C2776570981 @default.
• W4311760376 hasConcept C2777575956 @default.
• W4311760376 hasConcept C2777746085 @default.
• W4311760376 hasConcept C2778583881 @default.
• W4311760376 hasConcept C2778715743 @default.
• W4311760376 hasConcept C2780007028 @default.
• W4311760376 hasConcept C2780026749 @default.
• W4311760376 hasConcept C2780714102 @default.
• W4311760376 hasConcept C2780813298 @default.
• W4311760376 hasConcept C71924100 @default.
• W4311760376 hasConceptScore W4311760376C126322002 @default.
• W4311760376 hasConceptScore W4311760376C141071460 @default.
• W4311760376 hasConceptScore W4311760376C164705383 @default.
• W4311760376 hasConceptScore W4311760376C176752191 @default.
• W4311760376 hasConceptScore W4311760376C2776570981 @default.
• W4311760376 hasConceptScore W4311760376C2777575956 @default.
• W4311760376 hasConceptScore W4311760376C2777746085 @default.
• W4311760376 hasConceptScore W4311760376C2778583881 @default.
• W4311760376 hasConceptScore W4311760376C2778715743 @default.
• W4311760376 hasConceptScore W4311760376C2780007028 @default.
• W4311760376 hasConceptScore W4311760376C2780026749 @default.
• W4311760376 hasConceptScore W4311760376C2780714102 @default.
• W4311760376 hasConceptScore W4311760376C2780813298 @default.
• W4311760376 hasConceptScore W4311760376C71924100 @default.
• W4311760376 hasIssue "Supplement_K" @default.
• W4311760376 hasLocation W43117603761 @default.
• W4311760376 hasOpenAccess W4311760376 @default.
• W4311760376 hasPrimaryLocation W43117603761 @default.
• W4311760376 hasRelatedWork W1973893055 @default.
• W4311760376 hasRelatedWork W2145397396 @default.
• W4311760376 hasRelatedWork W2440997700 @default.
• W4311760376 hasRelatedWork W2786414754 @default.
• W4311760376 hasRelatedWork W2793664160 @default.
• W4311760376 hasRelatedWork W3113867246 @default.
• W4311760376 hasRelatedWork W3196531817 @default.
• W4311760376 hasRelatedWork W4242866055 @default.
• W4311760376 hasRelatedWork W4321123507 @default.
• W4311760376 hasRelatedWork W2554437933 @default.
• W4311760376 hasVolume "24" @default.
• W4311760376 isParatext "false" @default.
• W4311760376 isRetracted "false" @default.
• W4311760376 workType "article" @default.